Beijing Leadman Biochemistry Co.,Ltd. (SHE:300289)
China · Delayed Price · Currency is CNY 6.81
+0.09 (1.34%)
Apr 1, 2026, 3:04 PM CST
SHE:300289 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 326.31 | 336.32 | 421.98 | 675.94 | 540.94 |
Other Revenue | - | 33.91 | 39.57 | 30.04 | 23.12 |
| 326.31 | 370.23 | 461.55 | 705.98 | 564.06 | |
Revenue Growth (YoY) | -11.86% | -19.79% | -34.62% | 25.16% | 19.63% |
Cost of Revenue | 162.83 | 186.35 | 198.01 | 407.77 | 269.78 |
Gross Profit | 163.48 | 183.88 | 263.55 | 298.2 | 294.28 |
Selling, General & Admin | 153.98 | 176.94 | 183.21 | 205.67 | 179.42 |
Research & Development | 24.12 | 32.95 | 36.87 | 34.96 | 32.75 |
Other Operating Expenses | 8.9 | 10.67 | 11.79 | 12.65 | 11.07 |
Operating Expenses | 187 | 219.7 | 243.53 | 280.27 | 227.66 |
Operating Income | -23.52 | -35.83 | 20.02 | 17.94 | 66.62 |
Interest Expense | - | -0.3 | -0.65 | -1.29 | -2.15 |
Interest & Investment Income | 4.53 | 17.28 | 17.22 | 18.86 | 8 |
Currency Exchange Gain (Loss) | - | -0.38 | -0.81 | -0.75 | 1.2 |
Other Non Operating Income (Expenses) | 11.42 | -0.75 | -0.35 | -0.65 | -0.65 |
EBT Excluding Unusual Items | -7.57 | -19.98 | 35.42 | 34.11 | 73.01 |
Impairment of Goodwill | - | -71.13 | -14.88 | -30.53 | -20.41 |
Gain (Loss) on Sale of Investments | 1.73 | 14.33 | -1.85 | 1.99 | 3.47 |
Gain (Loss) on Sale of Assets | 0.59 | 0.01 | - | 0.45 | 1.34 |
Asset Writedown | -12.3 | -0.02 | -0.22 | -0.16 | -1.3 |
Legal Settlements | - | -0.06 | - | -32.6 | - |
Other Unusual Items | - | 3.67 | 6.07 | 1.57 | 2.69 |
Pretax Income | -17.54 | -73.18 | 24.53 | -25.16 | 58.8 |
Income Tax Expense | 6.11 | 1.03 | 1.87 | 10.87 | 11.62 |
Earnings From Continuing Operations | -23.65 | -74.21 | 22.66 | -36.03 | 47.18 |
Minority Interest in Earnings | 0.67 | -0.89 | -7.32 | -20.24 | -24.76 |
Net Income | -22.98 | -75.1 | 15.34 | -56.27 | 22.42 |
Net Income to Common | -22.98 | -75.1 | 15.34 | -56.27 | 22.42 |
Shares Outstanding (Basic) | 545 | 544 | 544 | 563 | 448 |
Shares Outstanding (Diluted) | 545 | 544 | 544 | 563 | 448 |
Shares Change (YoY) | 0.15% | -0.01% | -3.35% | 25.50% | 5.54% |
EPS (Basic) | -0.04 | -0.14 | 0.03 | -0.10 | 0.05 |
EPS (Diluted) | -0.04 | -0.14 | 0.03 | -0.10 | 0.05 |
Free Cash Flow | 11.57 | 33.18 | 112.11 | 69.81 | 74.56 |
Free Cash Flow Per Share | 0.02 | 0.06 | 0.21 | 0.12 | 0.17 |
Dividend Per Share | - | - | 0.010 | - | 0.020 |
Gross Margin | 50.10% | 49.67% | 57.10% | 42.24% | 52.17% |
Operating Margin | -7.21% | -9.68% | 4.34% | 2.54% | 11.81% |
Profit Margin | -7.04% | -20.29% | 3.32% | -7.97% | 3.98% |
Free Cash Flow Margin | 3.55% | 8.96% | 24.29% | 9.89% | 13.22% |
EBITDA | 23.21 | 18.67 | 79.05 | 76.87 | 122.16 |
EBITDA Margin | 7.11% | 5.04% | 17.13% | 10.89% | 21.66% |
D&A For EBITDA | 46.72 | 54.5 | 59.03 | 58.93 | 55.54 |
EBIT | -23.52 | -35.83 | 20.02 | 17.94 | 66.62 |
EBIT Margin | -7.21% | -9.68% | 4.34% | 2.54% | 11.81% |
Effective Tax Rate | - | - | 7.63% | - | 19.76% |
Revenue as Reported | - | 370.23 | 461.55 | 705.98 | 564.06 |
Advertising Expenses | - | 1.01 | 2.14 | 2.82 | 2.27 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.